Future Oncology

Papers
(The H4-Index of Future Oncology is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation128
The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer109
First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811105
FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma withFGFR2rearrangements94
Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities72
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy)69
An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer68
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA65
The abscopal effect of radiation therapy61
Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer60
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma60
Immune-based combinations for advanced hepatocellular carcinoma: shaping the direction of first-line therapy59
TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer58
KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma58
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial57
How does COVID-19 fear and anxiety affect chemotherapy adherence in patients with cancer56
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia51
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma50
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design49
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study44
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC44
MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer43
Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis42
Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing41
Organ tropism in solid tumor metastasis: an updated review40
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors40
Cost–effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma39
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer39
Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E)38
Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer38
Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials36
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies35
Perceptions of the COVID-19 vaccine among patients with cancer: a single-institution survey34
RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma34
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-41234
0.061490058898926